Current treatment approaches for acne are becoming inefficient and come with undesirable side effects; however, new options available and in the pipeline are getting better, according to professor Recep Dursun, M.D., of the department of dermatology and venereal diseases at Necmettin Erbakan University, in Konya, Turkey, who was the lead author of a recent paper published July 11, 2019 in Dermatologic Therapy.1
Topical antiandrogens, insulin-like growth factor-1 inhibitors, peroxisome proliferator activated receptor modulators, dapsone and probiotics are among many novel acne therapies that are available or in studies, the authors note.
Among these areas, recent advances include:
1. TOPICAL ANTIANDROGENS
While they’re still in clinical trials for acne treatment, topical antiandrogens could be an option for controlling sebogenesis in patients with especially moderate-to-severe refractory acne, according to the paper.
Researchers studying cortexolone 17ɑ-propionate (clascoterone), a topical androgen antagonist being investigated as an acne treatment in a phase 3 clinical trial, write that studies have shown that clascoterone is a potent and well-tolerated antiandrogen, according to a paper published May 2019 in the Journal of Drugs in Dermatology.2
“The study described herein elucidates for the first time the mechanism of action of clascoterone. Clascoterone was found to bind the androgen receptor (AR) with high affinity in vitro, inhibit AR-regulated transcription in a reporter cell line, and antagonize androgen-regulated lipid and inflammatory cytokine production in a dose-dependent manner in human primary sebocytes,” according to the Journal of Drugs in Dermatology. “In particular, when compared to another AR antagonist, spironolactone, clascoterone was significantly better at inhibiting inflammatory cytokine synthesis from sebocytes.”
Dr. Durson reports no relevant disclosures.
1. 1 Dursun R, Daye M, Durmaz K. Acne and rosacea: What’s new for treatment?. Dermatol Ther. 2019;:e13020.
2. Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro. J Drugs Dermatol. 2019;18(5):412-418.
3. Zouboulis CC, Bettoli V. Management of severe acne. Br J Dermatol. 2015;172 Suppl 1:27-36.
4. Lee YB, Byun EJ, Kim AHS. Potential Role of the Microbiome in Acne: A Comprehensive Review. J Clin Med. 2019;8(7).